Label: PROCTOCORT- hydrocortisone acetate suppository

  • NDC Code(s): 65649-511-12, 65649-511-24
  • Packager: Salix Pharmaceuticals, Inc
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated April 1, 2016

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Hydrocortisone Acetate is a corticosteroid designated chemically as pregn-4-ene-3, 20-dione, 21-(acetyloxy)-11, 17-dihydroxy-(11β) with the following structural formula:

    Proctocort Structural Formula

     

    Each rectal suppository contains hydrocortisone acetate, USP 30 mg in a specially blended hydrogenated vegetable oil base.

  • CLINICAL PHARMACOLOGY

    In normal subjects, about 26% of hydrocortisone acetate is absorbed when the suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces. Topical steroids are primarily effective because of their anti-inflammatory, anti-pruritic and vasoconstrictive action.

  • INDICATIONS AND USAGE

    Proctocort® Suppositories are indicated for use in inflamed hemorrhoids, postirradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani.

  • CONTRAINDICATIONS

    Proctocort® Suppositories are contraindicated in those patients having a history of hypersensitivity to hydrocortisone acetate or any of the components.

  • PRECAUTIONS

    Do not use Proctocort® Suppositories unless adequate proctologic examination is made.

    If irritation develops, the product should be discontinued and appropriate therapy instituted.

    In the presence of an infection, the use of an appropriate antifungal or anti-bacterial agent should be instituted. If a favorable response does not occur promptly, Proctocort® Suppositories should be discontinued until the infection has been adequately controlled.

    Carcinogenesis: No long term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.

    Pregnancy Category C: In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well controlled studies in pregnant women. Proctocort® Suppositories should only be used during pregnancy if the potential benefit justifies the risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

    Nursing Mothers: It is not known whether this drug is excreted in human milk and because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Proctocort® Suppositories, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. 

  • ADVERSE REACTIONS

    The following local adverse reactions have been reported with hydrocortisone acetate suppositories; burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, secondary infection.

    To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

  • DRUG ABUSE AND DEPENDENCE

    Drug abuse and dependence have not been reported in patients treated with hydrocortisone acetate suppositories.

  • OVERDOSAGE

    If signs and symptoms of systemic overdosage occur, discontinue use.

  • DOSAGE AND ADMINISTRATION

    For rectal administration. Detach one suppository from strip of suppositories. Remove the foil wrapper. Avoid excessive handling of the suppository which is designed to melt at body temperature. Insert suppository into the rectum with gentle pressure, pointed end first. Insert one suppository in the rectum twice daily, morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times a day or two suppositories twice daily. In factitial proctitis, the recommended duration of therapy is six to eight weeks or less, according to the response of the individual case.

  • HOW SUPPLIED

    Box of 12 suppositories - NDC 65649-511-12

    Box of 24 suppositories - NDC 65649-511-24

    Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Store away from heat. PROTECT FROM FREEZING.

    Manufactured for: Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA

    Protocort is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.

    © Valeant Pharmaceuticals North America LLC

    Rev. 04/2016

    9521400

    1P100 9L J1

    2201311

  • PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL PRINCIPAL DISPLAY PANEL - PROCTOCORT® 30 mg Carton Label

    NDC 65649-511-12

    Rx only

    PROCTOCORT®

    Hydrocortisone Acetate

    Rectal Suppositories

    For rectal use only.

    Not for oral use.

    30 mg                       12 Suppositories 

    ProctocortCarton.jpg 

     

  • INGREDIENTS AND APPEARANCE
    PROCTOCORT 
    hydrocortisone acetate suppository
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:65649-511
    Route of AdministrationRECTAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    HYDROCORTISONE ACETATE (UNII: 3X7931PO74) (HYDROCORTISONE - UNII:WI4X0X7BPJ) HYDROCORTISONE ACETATE30 mg
    Inactive Ingredients
    Ingredient NameStrength
    HYDROGENATED PALM OIL (UNII: 257THB963H)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    BUTYLATED HYDROXYANISOLE (UNII: REK4960K2U)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:65649-511-1212 in 1 BOX; Type 0: Not a Combination Product06/01/2004
    2NDC:65649-511-2424 in 1 BOX; Type 0: Not a Combination Product06/01/2004
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Unapproved drug other06/01/2004
    Labeler - Salix Pharmaceuticals, Inc (793108036)
    Establishment
    NameAddressID/FEIBusiness Operations
    Paddock Laboratories, LLC967694121MANUFACTURE(65649-511)